Sudhir R. Sahasrabudhe, Ph.D.
Chief Scientif Officer and Director
From 2010 to 2015 Dr. Sahasrabudhe has led Rines Therapeutics, a consultancy company. Dr. Sahasrabudhe was formerly the scientific founder of Myriad Proteomics/Prolexys Pharmaceuticals, Inc. and served as its Chief Executive Officer (2007-2010) and Chief Scientific Officer (2002-2010). He has developed PRLX 93936, a drug that entered Phase 1/2 clinical trials for multiple myeloma. From 2000 to 2002, he served as Executive Vice President for Research and Development for Myriad Genetics. Dr. Sahasrabudhe was member of the Board of Associates at MIT-Whitehead (2001-2007). He also served on the Board of Trustee’s at the University of Utah Research Foundation (2002-2008). At Sanofi-Aventis, Dr. Sahasrabudhe was the Head of US Biotechnology, responsible for identifying enabling technologies to develop novel therapeutic targets. He played a key role in creating a joint venture for developing novel technologies. Dr. Sahasrabudhe coordinated Lead Generation activities in a matrix setting to fulfill the quality IND needs of the U.S. R&D Center.
Paul J. Shami, M.D.
Co-Founder, Chief Medical Officer and Director
Dr. Shami is a Professor in the Division of Hematology and Hematologic Malignancies and member of the Huntsman Cancer Institute at the University of Utah. Dr. Shami has 25 years of experience in the treatment of cancer with a particular emphasis on hematologic malignancies. He also has 25 years of experience in cancer drug development, ranging from drug discovery to all phases of clinical trials. Dr. Shami served on the Developmental Therapeutics Study Section at the NCI and serves on the AML and myelodysplastic syndromes panels of the National Cancer Center Network.
Dr. Shami was the first investigator to observe that O2-aryl diazeniumdiolate NO donors are potent treatments for cancer. He is also the inventor of the micellar formulation of JS-K. In addition to JSKT, Dr. Shami is the co-founder of Lone Star Thiotherapies, a start-up company aiming at developing thiocarbamate/metal chelates for the treatment of cancer.
Joseph Nowoslawski, MD
Chief Executive Officer and Director
Dr. Nowoslawski earned a Bachelor’s Degree in Biology from Wayne State University and a Medical Degree from Michigan State University. He completed a residency in Emergency Medicine at the Medical College of Pennsylvania. Dr. Nowoslawski has over 30 years experience as a medical doctor and healthcare executive. He founded American Hospital Services Group (AHSG), a health care delivery and staffing company. He served as AHSG’s Medical Director reviewing aspects of healthcare delivery systems under healthcare reform initiatives as well as directing the company to successfully obtain an award from the United States Air Force exceeding $1 billion dollars. Dr. Nowoslawski has orchestrated the first strategic sourcing contract for his company in the state of Pennsylvania for all of the healthcare services provided in the state.
Dr. Nowoslawski is also a seasoned venture capital investor with extensive involvement in the venture community in Utah having invested in several biotech startup companies in the region. He is a member of the Salt Lake City Angels investment group, the Purpose Investor Network and is an active member of BioUtah. He has taught funding approaches for startups in the region and works with several philanthropic fund raising projects including the Sacred Circle Health Center in Salt Lake City. Prior to founding AHSG, Dr. Nowoslawski practiced clinically for a number of years in the SE Pennsylvania region, including maintaining the Directorship of Emergency Department of Fitzgerald Mercy Hospital, in Darby, PA and other institutions. Dr. Nowoslawski is certified by the American Board of Managed Care and the American Board of Forensic Examiners.
Dinesh Patel, Ph.D
Chairman of the Board of Directors
Dinesh Patel is the founder and managing director of Patel Family Investments (2014) and co-founded vSpring Capital ($400 million under management) in 2000 where he has been a founding managing director till October 2014. Prior to vSpring Capital, Dr. Patel was an active angel investor in over 20 biotech and technology companies. From 1985 – 1999 Dr. Patel served as Co-Founder, Chairman of The Board of Directors and President & CEO of TheraTech, Inc., a biotechnology company which he took public and eventually sold to Watson Pharmaceuticals (now Actavis). From 1999 to 2004 he managed Ashni Naturaceuticals, Inc., and Salus Therapeutics, Inc. Dr. Patel also served on the board of Mediconnect Global (now Verisk Analytics). Mediconnect was acquired by Verisk Analytics (VRSK) for over $377 million. Dr. Patel led the investments in Altea Therapeutics, American Academy, Athena Feminine Technologies, Axial Biotech, Coherex Medical, Exagen Diagnostics, Mirabilis Medica, Numira Biosciences, Lineagen, NanaMR, Q Therapeutics, Scintila, ZARS Pharma and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million
Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2013 Willem J Kolff Lifetime Achievement Award, the Ellis Island Medal of Honor, US Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah). He is also a charter member of The Indus Entrepreneurs (TiE). Dr. Patel served as co-chair of Governor Huntsman’s transition and he served as the Chairman of the USTAR Governing Authority board from 2006-2014. He is a member of the Life Sciences and Management Board at the University of Pennsylvania , on the University of Michigan’s President’s Advisory Group and on the University of Utah’s National Advisory Council. Born and raised in Zambia, Africa, Dr. Patel received his bachelor’s degree in Pharmacy at Gujarat University located in Ahmedabad, Gujarat, India, his master’s degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan.
Thomas P. Kennedy, M.D., M.P.H.
Dr. Kennedy earned his medical degree from Vanderbilt Medical School. He completed his internal medicine residency and pulmonary and critical care fellowship at the Johns Hopkins Hospital, and his occupational medicine residency and Masters in Public Health at the Johns Hopkins Bloomberg School of Hygiene and Public Health. He is board certified in Internal Medicine, Critical Care and Pulmonary Diseases. He is a member of the American Thoracic Society and American College of Chest Physicians.
Dr. Kennedy is a Research Professor of Medicine at Wake Forest University Baptist Medical Center. He was on the faculty of the University of Utah at the time of the founding of JSKT. He has held faculty appointments at the University of North Carolina, Duke, and Tulane University. Dr. Kennedy is a serial entrepreneur. His basic research interest centers on the anti-inflammatory pharmacology of sulfated polysaccharides. Dr. Kennedy has invented the non-anticoagulant heparin CX-01 (ODSH), currently in development for the treatment of acute myeloid leukemia. Dr. Kennedy has developed the combination of thiocarbamates with metals for the treatment of different malignant diseases. Dr. Kennedy also founded GlycoMira, a start-up biotechnology company developing hyaluronic acid derivatives for anti-inflammatory use in skin diseases.